Enveric Biosciences Inc ENVB, a biotechnology company specializing in neuroplastogen therapeutics for mental health conditions, has entered into a licensing agreement with MycoMedica Life Sciences.
Enveric will out-license its EVM201 program, including the drug candidate EB-002 (formerly EB-373), to MycoMedica. The partnership is set to bring forward the development of EB-002, a synthetic prodrug of psilocin for treating neuropsychiatric disorders, including depression.
See Also: Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Under the terms of the agreement, MycoMedica gains exclusive, global rights to EB-002, including its formulations, usage methods and associated medical devices.
MycoMedica will assume responsibility for all future preclinical, clinical, and commercial development of EB-002, with Enveric set to receive potential milestone payments totaling up to $62 million, plus royalties on sales. This agreement also grants MycoMedica sublicensing rights and cash buyout options.
Enveric's Strategic Move: Licensing EB-002 While Prioritizing EB-003
"Our strategic decision to license EB-002 is a testament to Enveric's commitment to innovation, collaboration, and efficiency, positioning both EB-002 and EB-003 for maximum impact in their respective treatment spaces," Joseph Tucker, Ph.D., CEO of Enveric said in an exclusive statement.
"This agreement allows us to remain true to our mission: driving transformative solutions in mental health through the pioneering work with EB-003, while enabling EB-002 to realize its potential in the hands of a capable partner," he added.
Meanwhile Sanjay Dubé, M.D., CEO and chief medical officer of MycoMedica also commented in a press release. "We are excited to enter into this licensing agreement with Enveric and continue the development of EB-002 as we seek to advance new treatment options for patients with neuropsychiatric disorders."
With EB-002 now in the hands of MycoMedica, Enveric is concentrating its resources on the development of EB-003. The novel neuroplastogen is seen as a groundbreaking treatment for depression, anxiety, and addiction disorders, with the company aiming to file an Investigational New Drug (IND) application in 2025.
Read Next:
Cover image made with AI.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.